| Outcome Measures: |
Primary: Change in HbA1c, Change from baseline to week 32 in Glycosylated Hemoglobin(HbA1c)., Week 32 | Secondary: Change in HbA1c, Change from baseline to week 20 in HbA1c., Week 20|Change in FPG, Change from baseline to week 20, 32 in Fasting Plasma Glucose(FPG)., Week 20，32|Proportion of participants who achieved HbA1c<7.0%，HbA1c≤6.5%, Proportion of participants who achieved HbA1c\<7.0%，HbA1c≤6.5% at week 20, 32., Week 20，32|Proportion of participants who achieved HbA1c<7.0%，HbA1c≤6.5% with no hypoglycemic event, Proportion of participants who achieved HbA1c\<7.0%，HbA1c≤6.5% with no confirmed symptomatic hypoglycemic event reported after treatment., Week 20，32|Change in Body Weight, Change from baseline to week 20, 32 in Body Weight., Week 20，32|Proportion of participants with Weight Loss≥5%, ≥10% and ≥15%, Proportion of participants with Weight Loss≥5%, ≥10% and ≥15% at week 20, 32., Week 20，32|Change in Diastolic and Systolic Blood Pressure, Change from baseline to week 32 in Diastolic and Systolic Blood Pressure., Week 32|Changes in Blood Lipids, Changes baseline to week 32 in Blood Lipids: Total Cholesterol, Low-density Lipoprotein Cholesterol, High-Density Lipoprotein Cholesterol, and Triglycerides., Week 32|Incidence and severity of Adverse Events, Incidence and severity of Adverse Events during treatment., Week 32
|
